Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Chuikyo Approves 26 Products Including Takecab, Zelboraf for Listing
February 19, 2015
- Add Risk of Interstitial Pneumonia to Eliquis Package Insert: MHLW
February 18, 2015
- Abe Calls for Shrewd Strategies for Pharmas, Industry Consolidation as Necessary
February 18, 2015
- LDP Pharma Policy Study Group on Alert for 3 Consecutive Years of Drug Price Cuts
February 17, 2015
- MHLW Approves 309 Generic Products Ahead of June Listing; 32 Companies Obtain Approval for Plavix Generics Including AGs
February 17, 2015
- Panel Approves 43 More Diseases as Designated Intractable Diseases
February 17, 2015
- Gilead Told to Improve Biz Practice in Japan over Delayed ADR Reporting
February 16, 2015
- Health Minister to Kick Off Roundtable for Healthcare Policy for 2035 This Month
February 16, 2015
- PAFSC’s Second Committee to Discuss Celgene’s Multiple Myeloma Treatment Pomalidomide on Feb. 26
February 13, 2015
- PMDA Plans Manufacturing Inspections for 2 Regenerative Medicine Products This Year
February 12, 2015
- MHLW Pursuing Quick Approval of Japan-OK’ed Drugs in Emerging Markets
February 10, 2015
- Health Minister Says to Mull Revising Generic Share Target
February 10, 2015
- National Cancer Center Announces Guidelines for Clinical Trial Monitoring and Auditing
February 10, 2015
- Editor’s Pick: Five Healthcare News Headlines for Jan. 26 - Feb. 8
February 9, 2015
- PAFSC 1st Committee to Discuss Actelion’s PAH Treatment on Feb. 20
February 9, 2015
- Panel OKs Intractable Disease Designation of Muscular Dystrophy
February 6, 2015
- NHI Price System that Would Undermine Wholesalers’ Stable Supply Ability Unacceptable: HIB Director-General
February 6, 2015
- GSK Ordered to Issue Blue Letter on Lamictal
February 5, 2015
- MHLW Plans Business Suspension Order for Novartis
February 5, 2015
- R&D Tax Credit Overhaul Likely in FY2017, but In a Way to Spur Investments: LDP’s Goto
February 4, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…